- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million Initial Public Offering for Polyrizon Ltd. | 178 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ:PLRZ).About Polyrizon Ltd.Polyrizon... ► Artikel lesen | |
| Mi | Polyrizon Ltd.: Polyrizon Announces Closing of $4.2 Million Initial Public Offering | 46 | GlobeNewswire (Europe) | Raanana, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels... ► Artikel lesen | |
| Di | Polyrizon Ltd.: Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker "PLRZ" | 84 | GlobeNewswire (Europe) | Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels... ► Artikel lesen | |
| 21.10. | Polyrizon Ltd. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 02.10. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 2 | SEC Filings | ||
| 23.09. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 16.09. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 04.09. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 19.08. | SciSparc and Polyrizon sign global agreement for pain therapy | 1 | Pharmaceutical Technology | ||
| 19.08. | Polyrizon pays $3M for license to SciSparc's preclinical cannabinoid pain therapy | 1 | FierceBiotech | ||
| 16.08. | SciSparc licenses SCI-160 pain drug program to Polyrizon | 2 | Seeking Alpha | ||
| 14.08. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 20.05. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,050 | +0,17 % | Biotech Report: Evotec und Qiagen gehen leichter ins Wochenende | (shareribs.com) Frankfurt / New York 25.10.2024 - Die Biotechnologiewerte zeigten sich im deutschen Handel überwiegend leichter. Aufwärts ging es für Vita34, abwärts für Evotec und Qiagen. An der Wall... ► Artikel lesen | |
| EVOTEC | 7,090 | -2,27 % | Evotec Aktie: Kurssprung trotz Quartalsverlust überrascht Markt | ||
| HARMONY BIOSCIENCES | 32,220 | -5,60 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,870 | -1,52 % | Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 | Long-term improvements observed in the quartet of findings defining disease modification supports atacicept's potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN... ► Artikel lesen | |
| BIONTECH | 103,30 | -1,62 % | BioTech - Folgen auf kuriose Kurse jetzt Übernahmen? Evotec, Bayer, Vidac Pharma und BioNTech im Fadenkreuz | Der Biotechsektor steht erneut im Fokus. Seit der Übernahme von MorphoSys zu Anfang des Jahres dreht sich das Spekulationskarussell wieder. Ist demnächst Evotec dran oder vielleicht Vidac Pharma? Der... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,73 | +0,07 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
| NUVALENT | 89,37 | -1,17 % | Deerfield Management verkauft Nuvalent-Aktien für 195,5 Millionen US-Dollar | ||
| GALAPAGOS NV | 24,620 | -6,25 % | Galapagos NV: Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update | We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing... ► Artikel lesen | |
| BB BIOTECH | 38,850 | -0,77 % | Ihre wichtigsten Termine: Alle Blicke auf: Mercedes-Benz Group AG, Colgate-Palmolive, BB Biotech & Sanofi | © Foto: Sebastian Gollnow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| BIOMEA FUSION | 9,400 | -10,00 % | Biomea Fusion, Inc.: Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule ... | Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to increased... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 14,610 | +1,53 % | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 42,920 | -1,33 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
| GUBRA | 57,00 | -5,00 % | AKTIONÄR-Depotwert Gubra: Bald wie Viking Therapeutics? | Die Aktie von Viking Therapeutics hat in der Vorwoche massive Kursgewinne verzeichnet. Vor allem die Aussicht auf weiteren Studiendaten zum Adipositas-Hoffnungsträger VK2735 Anfang November sowie die... ► Artikel lesen | |
| ARVINAS | 26,540 | -4,19 % | Arvinas Inc.: Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 - - Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 40,980 | +8,13 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024 |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,380 Euro und damit -16,87 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.
